RxDoctor Payments Data

Thomas Santilli, MD

Cardiovascular Disease · Meadowbrook, PANPI 1215939756

Payments from drug & device makers

$7,910in general payments, 2019–2025

Across 492 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$908
  • Johnson & Johnson$741
  • Novartis$717
  • Pfizer$696
  • Sanofi-aventis U.S. LLC$634
  • E.r. Squibb & Sons, L.L.C.$594
  • plus $4K from 29 others

What the payments were for

  • Food & beverage$7,910100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,910 in reported general payments places this provider in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,832
Medicare patients
982
Services billed
2,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban346$413,324
XareltoRivaroxaban108$105,262
MultaqDronedarone Hcl53$65,368
EntrestoSacubitril/Valsartan35$39,012
Repatha SureclickEvolocumab25$35,674
Rosuvastatin Calcium379$10,202
Praluent PenAlirocumab17$9,885
Metoprolol Succinate356$8,903
EdarbyclorAzilsartan Med/Chlorthalidone16$5,599
Dofetilide24$4,934
Ezetimibe186$4,453
Atorvastatin Calcium230$4,174
Nebivolol Hcl51$2,305
Atenolol128$2,098
Verapamil ErVerapamil Hcl48$1,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$696$413,324346 claims
Johnson & JohnsonXarelto$741$105,262108 claims
Sanofi-aventis U.S. LLCMultaq$634$65,36853 claims
NovartisEntresto$717$39,01235 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$84$5,59916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →